Metastatic Gastric Cancer Clinical Trial
Official title:
Improving the Approach to and Management of the Older Patient With Metastatic Gastric Cancer
The purpose of this study is to enhance the care of older metastatic gastric cancer (mGC) patients by increasing awareness among oncology providers of the unique aspects of care required for older patients. The goal of the study is to educate providers on the utility of geriatric assessment in guiding therapy of older mGC patients. The investigators will also assess the feasibility and benefit of incorporating geriatric self-assessments into clinical practice. The study will include four phases.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 70 Years and older |
Eligibility | Inclusion Criteria: 1. Ability to read and understand English, ability to sign consent, and complete a self-assessment evaluation. 2. Evidence of mGC (mGE junction cancer allowed). Patients can be enrolled at any stage of their treatment or disease course. 3. Ongoing active therapy for mGC. Patients can be treated with any type of therapy including chemotherapy, immunotherapy or Her-2 targeted therapy. 4. Life expectancy =3 months. Exclusion Criteria: 1. =69 years old. 2. Inability to read and understand English. 3. No evidence of mGC. 4. Not on active therapy. 5. Life expectancy <3 months. |
Country | Name | City | State |
---|---|---|---|
United States | Fox Chase Cancer Center | Philadelphia | Pennsylvania |
United States | Temple University Hospital | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Fox Chase Cancer Center | Eli Lilly and Company, National Comprehensive Cancer Network |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of geriatric abnormalities detected. (Tool used: Comprehensive Geriatric Assessment) | Investigators will test the proportions of patients having at least one abnormality detected by the Comprehensive Geriatric Assessment that was missed in the standard clinical assessment compared to a null-hypothesis rate of 5%.
The Comprehensive Geriatric Assessment includes the following scales: Eastern Cooperative Oncology Group Performance Status, Self-rated Performance Status, Katz Activities of Daily Living scale, Lawton Instrumental Activities of Daily Live Scale, Timed Up and Go, Number of Falls in past 6 months, Medical Social Support Scale, Geriatric Depression Scale, National Comprehensive Cancer Center Distress Thermometer, Blessed Orientation Memory Concentration Scale, Charlson Comorbidity Index, Body Mass index,Mini Nutritional Assessment, Cancer and Aging Research Group Chemotherapy Toxicity Prediction Calculator, Comprehensive Score for Financial Toxicity - Functional Assessment of Chronic Illness Therapy scale |
18 Months | |
Primary | Percentage of treatment plan changes. (Count # of treatment changes 2-3 months after comprehensive geriatric assessment. Site coordinators will complete follow-up chart review of each patient to see what, if any, changes were made) | Investigators will assess the percentage of physician reported cases whose treatment plan was modified due to responses on the Comprehensive Geriatric Assessment. | 18 months | |
Secondary | Provider perception (Review of Geriatric Assessment Questionnaire) | Measurement of provider perception of the efficacy and feasibility of the didactic educational session via questionnaire | 18 months | |
Secondary | Fitbit assessed functional status. Fitbit data: step count | We aim to determine the feasibility of using fitbits in this patient population and evaluate the correlation between step count, physician recorded performance status, and scores on functional assessment in the comprehensive geriatric assessment.
We will compare data collected from the FitBit to both the physician-reported and CGA-identified functional status (Timed Up and Go, Activities of Daily Living, Instrumental Activities of Daily Living, and number of falls in the past 6 months) in each patient. |
18 months | |
Secondary | Fitbit assessed functional status. Fitbit data: distance logged | We aim to determine the feasibility of using fitbits in this patient population and evaluate the correlation between distance logged, physician recorded performance status, and scores on functional assessment in the comprehensive geriatric assessment.
We will compare data collected from the FitBit to both the physician-reported and CGA-identified functional status (Timed Up and Go, Activities of Daily Living, Instrumental Activities of Daily Living, and number of falls in the past 6 months) in each patient. |
18 months | |
Secondary | Fitbit assessed functional status. Fitbit data: moderately active, lightly active, and sedentary minute categorization. | We aim to determine the feasibility of using fitbits in this patient population and evaluate the correlation between moderately active, lightly active, and sedentary minute categorization, physician recorded performance status, and scores on functional assessment in the comprehensive geriatric assessment.
We will compare data collected from the FitBit to both the physician-reported and CGA-identified functional status (Timed Up and Go, Activities of Daily Living, Instrumental Activities of Daily Living, and number of falls in the past 6 months) in each patient. |
18 months | |
Secondary | Fitbit assessed functional status. Fitbit data: floors climbed | We aim to determine the feasibility of using fitbits in this patient population and evaluate the correlation between floors climbed, physician recorded performance status, and scores on functional assessment in the comprehensive geriatric assessment.
We will compare data collected from the FitBit to both the physician-reported and CGA-identified functional status (Timed Up and Go, Activities of Daily Living, Instrumental Activities of Daily Living, and number of falls in the past 6 months) in each patient. |
18 months | |
Secondary | Fitbit assessed functional status. Fitbit data: calories burned | We aim to determine the feasibility of using fitbits in this patient population and evaluate the correlation between calories burned, physician recorded performance status, and scores on functional assessment in the comprehensive geriatric assessment.
We will compare data collected from the FitBit to both the physician-reported and CGA-identified functional status (Timed Up and Go, Activities of Daily Living, Instrumental Activities of Daily Living, and number of falls in the past 6 months) in each patient. |
18 months | |
Secondary | Fitbit assessed functional status. Fitbit data: heart rate | We aim to determine the feasibility of using fitbits in this patient population and evaluate the correlation between heart rate, physician recorded performance status, and scores on functional assessment in the comprehensive geriatric assessment.
We will compare data collected from the FitBit to both the physician-reported and CGA-identified functional status (Timed Up and Go, Activities of Daily Living, Instrumental Activities of Daily Living, and number of falls in the past 6 months) in each patient. |
18 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02668380 -
An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer
|
N/A | |
Completed |
NCT03121807 -
Home Parenteral Nutrition for Malnourished Unresectable Stage IV Gastric Cancer
|
N/A | |
Recruiting |
NCT04358354 -
Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer
|
Phase 3 | |
Completed |
NCT01099527 -
A Trial of RAD001/Capecitabine in Refractory Gastric Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00253370 -
Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer
|
Phase 2 | |
Recruiting |
NCT02002195 -
Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer
|
||
Recruiting |
NCT06008925 -
Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05714124 -
Liver Embolization Approaches for Tumor Management
|
||
Recruiting |
NCT02855788 -
Metronomic Chemotherapy in Advanced Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT03154983 -
The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer
|
Phase 2 | |
Not yet recruiting |
NCT04263870 -
Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
|
Phase 2 | |
Active, not recruiting |
NCT01359397 -
Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT04739202 -
Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)
|
Phase 2 | |
Completed |
NCT03409848 -
Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT05859477 -
Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT05955833 -
89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study
|
Phase 1 | |
Terminated |
NCT01528501 -
Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008)
|
Phase 2 | |
Completed |
NCT03751761 -
GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT05024812 -
Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03614013 -
Resistance to Immunotherapy in Gastric Cancer
|